The FDA in May added the EpiPen to its tally of. Hundreds of patients across the country reported trouble getting prescriptions filled due to manufacturing issues at a Pfizer factory that makes the devices in partnership with Mylan.
The drug agency in 2016 declined to approve Teva’s generic EpiPen, before itshit the news.
Mylan had a $1 billion in brand-name EpiPen sales that year, but that figure fell by more than half in 2017 as its generic version eroded brand-name sales.MORE NEWS: El Sereno Recreation Center Vaccination Site To Close Wednesday, Will Be Replaced With New East LA Site
On Thursday afternoon, Mylan shares fell 0.2 percent, while those of Teva increased 6.8 percent.